Agammaglobulinemia

Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
NCT00322556 | PHASE 3 | INTERVENTIONAL

The objectives of this trial are the assessment of safety and efficacy of IgPro10 in patients with PID, and the assessment of tolerability of high infusion rates. To demonstrate safety, the number of infusions temporally associated with AEs, the rate, severity and relationship of all AEs and the vital sign changes during each infusion will be evaluated.

Trial Information
10 Sites
55 Participants
Recruiting
4 Years to 71 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

SUBMIT
Contact CSL Behring for facility details
Los Angeles,California,United States,90027
Contact CSL Behring for facility details
Centennial,Colorado,United States,80112
Contact CSL Behring for facility details
North Palm Beach,Florida,United States,33408
Contact CSL Behring for facility details
St. Petersburg,Florida,United States,33701
Contact CSL Behring for facility details
Fort Wayne,Indiana,United States,46815
Contact CSL Behring for facility details
Indianapolis,Indiana,United States,46202
Contact CSL Behring for facility details
Iowa City,Iowa,United States,52242
Contact CSL Behring for facility details
Rochester,Minnesota,United States,55905
Contact CSL Behring for facility details
St. Louis,Missouri,United States,63104
Contact CSL Behring for facility details
Dallas,Texas,United States,75230

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov